{
    "nctId": "NCT03524261",
    "briefTitle": "Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer",
    "officialTitle": "Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Objective response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18-75 years old\n* The patient is diagnosed as advanced breast cancer,MUC1 is positive\n* There is at least one tumor should be measured,and length\u226510mm of focus not at lymph node or length\u226510mm of focus at lymph node\n* The patient can't tolerate system(systemic chemotherapy/molecular targeted therapy) or local therapies\n* If the patient received adjuvant chemotherapy after local treatment,the time should be more than 4 weeks after the end of chemotherapy, and disease progression or metastasis patients can also assigned into the group\n* The time of surgical treatment\u2265 3 months ;At the end of the intervention,radiotherapy and the end of the ablation time is more than 4 weeks\n* The expected survival time \u226512 weeks\n* The patient did not took any antitumor drugs within 4 weeks(any antitumor drugs, Chinese patent medicine including Delisheng injection,Kanglaite injection, Aidi injection\n* No serious disease are conflicts with the solution(such as autoimmune disease,immunodeficiency,organ transplantation)\n* Sign the informed consent\n\nExclusion Criteria:\n\n* medium or above ascites\n* Patient of second primary tumor or multiple primary cancer\n* Patients of T cell lymphoma\u3001myeloma,and patients are using immunosuppressant\n* Systemic autoimmune diseases, allergic constitution or immunocompromised patients\n* Patients of chronic diseases need immune stimulant or hormone therapy\n* Patients of active bleeding or coagulant function abnormality\uff08PT\\>16s\u3001APTT\\>43s\u3001TT\\>21s\u3001INR\u22652\uff09,and patients of bleeding tendency or are receiving thrombolysis and anticoagulation and antiplatelet therapy\n* Women who is pregnant or during breast feeding or plan to pregnant in 2 years,and not willing to contraception during the test\n* Patients with brain\u3001dura mater metastases or history of psychogenic\n* Gastrointestinal bleeding in the past six months or have clear gastrointestinal bleeding tendency,such as: patients of local active ulcerative lesions, defecate occult blood + + above shall not enter into group; defecate occult blood + depend on gastroscopy\n* Patients with severe stomach/esophageal varices and need for intervention treatment\n* Patients with abdominal fistula, gastrointestinal perforation or abdominal abscess within 4 weeks before the first treatment\n* Positive for HIV antibody\n* Patients who are allergic to computed tomography (CT) and magnetic resonance imaging (MRI) contrast agents at the same time, can't imaging assay\n* Patients accepted any experimental drugs or pilot medical apparatus and instruments in the past 4 weeks of first treatment\n* Other reasons the researchers think not suitable",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}